69 related articles for article (PubMed ID: 23489123)
1. Drugs targeting integrins for cancer therapy.
Binder M; Trepel M
Expert Opin Drug Discov; 2009 Mar; 4(3):229-41. PubMed ID: 23489123
[TBL] [Abstract][Full Text] [Related]
2. Vascular integrins in tumor angiogenesis: mediators and therapeutic targets.
Alghisi GC; Rüegg C
Endothelium; 2006; 13(2):113-35. PubMed ID: 16728329
[TBL] [Abstract][Full Text] [Related]
3. Integrin-Targeted Peptide- and Peptidomimetic-Drug Conjugates for the Treatment of Tumors.
Arosio D; Manzoni L; Corno C; Perego P
Recent Pat Anticancer Drug Discov; 2017; 12(2):148-168. PubMed ID: 28164756
[TBL] [Abstract][Full Text] [Related]
4. Targeting integrins in hepatocellular carcinoma.
Wu Y; Qiao X; Qiao S; Yu L
Expert Opin Ther Targets; 2011 Apr; 15(4):421-37. PubMed ID: 21332366
[TBL] [Abstract][Full Text] [Related]
5. A conjugate of camptothecin and a somatostatin analog against prostate cancer cell invasion via a possible signaling pathway involving PI3K/Akt, alphaVbeta3/alphaVbeta5 and MMP-2/-9.
Sun LC; Luo J; Mackey LV; Fuselier JA; Coy DH
Cancer Lett; 2007 Feb; 246(1-2):157-66. PubMed ID: 16644105
[TBL] [Abstract][Full Text] [Related]
6. The alpha4beta1 and alpha5beta1 integrins mediate engraftment of granulocyte-colony-stimulating factor-mobilized human hematopoietic progenitor cells.
Carstanjen D; Gross A; Kosova N; Fichtner I; Salama A
Transfusion; 2005 Jul; 45(7):1192-200. PubMed ID: 15987366
[TBL] [Abstract][Full Text] [Related]
7. Phase II evaluations of cilengitide in asymptomatic patients with androgen-independent prostate cancer: scientific rationale and study design.
Beekman KW; Colevas AD; Cooney K; Dipaola R; Dunn RL; Gross M; Keller ET; Pienta KJ; Ryan CJ; Smith D; Hussain M
Clin Genitourin Cancer; 2006 Mar; 4(4):299-302. PubMed ID: 16729916
[TBL] [Abstract][Full Text] [Related]
8. Adenovirus-mediated thymidine kinase gene therapy for recurrent ovarian cancer: expression of coxsackie-adenovirus receptor and integrins alphavbeta3 and alphavbeta5.
Hasenburg A; Fischer DC; Tong XW; Rojas-Martinez A; Kaufman RH; Ramzy I; Kohlberger P; Orlowska-Volk M; Aguilar-Cordova E; Kieback DG
J Soc Gynecol Investig; 2002; 9(3):174-80. PubMed ID: 12009393
[TBL] [Abstract][Full Text] [Related]
9. Potential of Integrin Inhibitors for Treating Ovarian Cancer: A Literature Review.
Kobayashi M; Sawada K; Kimura T
Cancers (Basel); 2017 Jul; 9(7):. PubMed ID: 28698469
[TBL] [Abstract][Full Text] [Related]
10. Role of α5β1 and αvβ3 integrins in relation to adhesion and spreading dynamics of prostate cancer cells interacting with fibronectin under in vitro conditions.
Stachurska A; Elbanowski J; Kowalczyńska HM
Cell Biol Int; 2012 Oct; 36(10):883-92. PubMed ID: 22686483
[TBL] [Abstract][Full Text] [Related]
11. Role of hypoxia and extracellular matrix-integrin binding in the modulation of angiogenic growth factors secretion by retinal pigmented epithelial cells.
Mousa SA; Lorelli W; Campochiaro PA
J Cell Biochem; 1999 Jul; 74(1):135-43. PubMed ID: 10381270
[TBL] [Abstract][Full Text] [Related]
12. Microglial expression of alphavbeta3 and alphavbeta5 integrins is regulated by cytokines and the extracellular matrix: beta5 integrin null microglia show no defects in adhesion or MMP-9 expression on vitronectin.
Milner R
Glia; 2009 May; 57(7):714-23. PubMed ID: 18985734
[TBL] [Abstract][Full Text] [Related]
13. Development of integrins in the vasculature of germinal matrix, cerebral cortex, and white matter of fetuses and premature infants.
Dummula K; Vinukonda G; Xu H; Hu F; Zia MT; Braun A; Shi Q; Wolk J; Ballabh P
J Neurosci Res; 2010 May; 88(6):1193-204. PubMed ID: 19960540
[TBL] [Abstract][Full Text] [Related]
14. Integrin alphavbeta3 is not significantly implicated in the anti-migratory effect of anti-angiogenic urokinase kringle domain.
O E; Kim HK; Hong SH; Kim CK; Hong YK; Joe YA
Oncol Rep; 2008 Sep; 20(3):631-6. PubMed ID: 18695916
[TBL] [Abstract][Full Text] [Related]
15. The relationship between the cyclic-RGDfK ligand and αvβ3 integrin receptor.
Mondal G; Barui S; Chaudhuri A
Biomaterials; 2013 Aug; 34(26):6249-60. PubMed ID: 23702147
[TBL] [Abstract][Full Text] [Related]
16. Role of alpha5beta1 and alphavbeta3 integrins on smooth muscle cell spreading and migration in fibrin gels.
Ikari Y; Yee KO; Schwartz SM
Thromb Haemost; 2000 Oct; 84(4):701-5. PubMed ID: 11057873
[TBL] [Abstract][Full Text] [Related]
17. Zoledronate inhibits alphavbeta3 and alphavbeta5 integrin cell surface expression in endothelial cells.
Bellahcène A; Chaplet M; Bonjean K; Castronovo V
Endothelium; 2007; 14(2):123-30. PubMed ID: 17497369
[TBL] [Abstract][Full Text] [Related]
18. Enhanced pathological angiogenesis in mice lacking beta3 integrin or beta3 and beta5 integrins.
Reynolds LE; Wyder L; Lively JC; Taverna D; Robinson SD; Huang X; Sheppard D; Hynes RO; Hodivala-Dilke KM
Nat Med; 2002 Jan; 8(1):27-34. PubMed ID: 11786903
[TBL] [Abstract][Full Text] [Related]
19. Increased expression of the coxsackie and adenovirus receptor downregulates αvβ3 and αvβ5 integrin expression and reduces cell adhesion and migration.
Majhen D; Stojanović N; Špeljko T; Brozovic A; De Zan T; Osmak M; Ambriović-Ristov A
Life Sci; 2011 Aug; 89(7-8):241-9. PubMed ID: 21712047
[TBL] [Abstract][Full Text] [Related]
20. Blocking αvβ3 integrin by a recombinant RGD disintegrin impairs VEGF signaling in endothelial cells.
Montenegro CF; Salla-Pontes CL; Ribeiro JU; Machado AZ; Ramos RF; Figueiredo CC; Morandi V; Selistre-de-Araujo HS
Biochimie; 2012 Aug; 94(8):1812-20. PubMed ID: 22561350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
